Menu
← Oncology Approval Tracker
FDA DECISION ·
Itovebi + palbociclib + fulvestrant
inavolisib with palbociclib and fulvestrant · Genentech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with endocrine-resistant, PIK3CA-mutated, HR-positive and HER2-negative locally advanced or metastatic breast cancer after recurrence during or after adjuvant endocrine therapy; use with palbociclib and fulvestrant after FDA-approved testing.
LAMPGEN ANALYSIS
Why it matters
The triplet combines a PI3K-alpha inhibitor with CDK4/6 inhibition and endocrine therapy for a mutation-defined population.
What research teams should watch
Record the adjuvant endocrine timeline and mutation result, and plan baseline and serial glucose checks alongside blood counts.
PRIMARY RECORDS